OBJECTIVE:Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. METHODS: In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. RESULTS: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. CONCLUSIONS:Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.
RCT Entities:
OBJECTIVE:Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism. Less is known about the long-term effects of risperidone exposure in this population. We examined the tolerability, safety, and therapeutic benefit of risperidone exposure over a 1-2 year follow-up period. METHODS: In a naturalistic study, 84 children and adolescents 5-17 years of age (from an original sample of 101) were assessed an average of 21.4 months after initial entry into a placebo-controlled 8 week trial of risperidone for children and adolescents with autism and severe irritability. They were assessed at baseline and at follow-up on safety and tolerability measures (blood, urinalysis, electrocardiogram [ECG], medical history, vital signs, neurological symptoms, other adverse events), developmental measures (adaptive behavior, intelligence quotient [IQ]), and standardized rating instruments. Treatment over the follow-up period, after completion of protocol participation, was uncontrolled. Statistical analyses assessed outcome over time with or without prolonged risperidone therapy. RESULTS: Two-thirds of the 84 subjects continued to receive risperidone (mean 2.47 mg/day, S.D. 1.29 mg). At follow-up, risperidone was associated with more enuresis, more excessive appetite, and more weight gain, but not more adverse neurological effects. No clinically significant events were noted on blood counts, chemistries, urinalysis, ECG, or interim medical history. Regardless of drug condition at follow-up, there was considerable improvement in maladaptive behavior compared with baseline, including core symptoms associated with autism. Height and weight gains were elevated with risperidone. Social skills on Vineland Adaptive Behavior Scale (VABS) improved with risperidone. Parent-rated Aberrant Behavior Checklist (ABC) Irritability subscale scores were reduced in those taking risperidone at follow-up. Several other measures of maladaptive behavior (some related to socialization) also showed improved functioning in association with risperidone on the ABC or on the Modified Real Life Rating Scale. CONCLUSIONS: Increased appetite, weight gain, and enuresis are risks associated with long-term risperidone. Our data suggest that these risks were balanced by longer-term behavioral and social benefits for many children over 1.8 years of ongoing treatment.
Authors: L E Arnold; M G Aman; A Martin; A Collier-Crespin; B Vitiello; E Tierney; R Asarnow; F Bell-Bradshaw; B J Freeman; P Gates-Ulanet; A Klin; J T McCracken; C J McDougle; J J McGough; D J Posey; L Scahill; N B Swiezy; L Ritz; F Volkmar Journal: J Autism Dev Disord Date: 2000-04
Authors: Laurence L Greenhill; Benedetto Vitiello; Mark A Riddle; Prudence Fisher; Erin Shockey; John S March; Jerome Levine; Jane Fried; Howard Abikoff; Julie M Zito; James T McCracken; Robert L Findling; James Robinson; Thomas B Cooper; Mark Davies; Elena Varipatis; Michael J Labellarte; Lawrence Scahill; John T Walkup; Lisa Capasso; Jennifer Rosengarten Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-06 Impact factor: 8.829
Authors: Andrés Martin; Lawrence Scahill; George M Anderson; Michael Aman; L Eugene Arnold; James McCracken; Christopher J McDougle; Elaine Tierney; Shirley Chuang; Benedetto Vitiello Journal: Am J Psychiatry Date: 2004-06 Impact factor: 18.112
Authors: Laurence L Greenhill; Benedetto Vitiello; Howard Abikoff; Jerome Levine; John S March; Mark A Riddle; Lisa Capasso; Thomas B Cooper; Mark Davies; Prudence Fisher; Robert L Findling; Jane Fried; Michael J Labellarte; James T McCracken; Don McMahon; James Robinson; Anne Skrobala; Lawrence Scahill; Elena Varipatis; John T Walkup; Julie M Zito Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-06 Impact factor: 8.829
Authors: Benedetto Vitiello; Mark A Riddle; Laurence L Greenhill; John S March; Jerome Levine; Russell J Schachar; Howard Abikoff; Julie M Zito; James T McCracken; John T Walkup; Robert L Findling; James Robinson; Thomas B Cooper; Mark Davies; Elena Varipatis; Michael J Labellarte; Lawrence Scahill; Lisa Capasso Journal: J Am Acad Child Adolesc Psychiatry Date: 2003-06 Impact factor: 8.829
Authors: James T McCracken; James McGough; Bhavik Shah; Pegeen Cronin; Daniel Hong; Michael G Aman; L Eugene Arnold; Ronald Lindsay; Patricia Nash; Jill Hollway; Christopher J McDougle; David Posey; Naomi Swiezy; Arlene Kohn; Lawrence Scahill; Andres Martin; Kathleen Koenig; Fred Volkmar; Deirdre Carroll; Allison Lancor; Elaine Tierney; Jaswinder Ghuman; Nilda M Gonzalez; Marco Grados; Benedetto Vitiello; Louise Ritz; Mark Davies; James Robinson; Don McMahon Journal: N Engl J Med Date: 2002-08-01 Impact factor: 91.245
Authors: Oakleigh M Folkes; Rita Báldi; Veronika Kondev; David J Marcus; Nolan D Hartley; Brandon D Turner; Jade K Ayers; Jordan J Baechle; Maya P Misra; Megan Altemus; Carrie A Grueter; Brad A Grueter; Sachin Patel Journal: J Clin Invest Date: 2020-04-01 Impact factor: 14.808
Authors: Lan Chi Vo; Christopher Snyder; Courtney McCracken; Christopher J McDougle; James T McCracken; Michael G Aman; Elaine Tierney; L Eugene Arnold; Daniel Levi; Michael Kelleman; Deirdre Carroll; John Morrissey; Benedetto Vitiello; Lawrence Scahill Journal: J Child Adolesc Psychopharmacol Date: 2016-10-11 Impact factor: 2.576
Authors: C Lindsay DeVane; Jane M Charles; Ruth K Abramson; John E Williams; Laura A Carpenter; Sarah Raven; Frampton Gwynette; Craig A Stuck; Mark E Geesey; Catherine Bradley; Jennifer L Donovan; Alicia G Hall; Shelley T Sherk; Nancy R Powers; Eve Spratt; Anne Kinsman; Markus J Kruesi; John E Bragg Journal: Pharmacotherapy Date: 2019-05-29 Impact factor: 4.705
Authors: Lawrence Scahill; Sangchoon Jeon; Susan J Boorin; Christopher J McDougle; Michael G Aman; James Dziura; James T McCracken; Sonia Caprio; L Eugene Arnold; Ginger Nicol; Yanhong Deng; Saankari A Challa; Benedetto Vitiello Journal: J Am Acad Child Adolesc Psychiatry Date: 2016-03-07 Impact factor: 8.829
Authors: Ian M Shochet; Beth R Saggers; Suzanne B Carrington; Jayne A Orr; Astrid M Wurfl; Bonnie M Duncan; Coral L Smith Journal: Clin Child Fam Psychol Rev Date: 2016-06
Authors: Sarah E Fitzpatrick; Laura Srivorakiat; Logan K Wink; Ernest V Pedapati; Craig A Erickson Journal: Neuropsychiatr Dis Treat Date: 2016-06-23 Impact factor: 2.570